Sedvall G, Karlsson P, Lundin A, Anvret M, Suhara T, Halldin C, Farde L
Department of Clinical Neuroscience, Karolinska Hospital and Institute, Stockholm, Sweden.
Eur Arch Psychiatry Clin Neurosci. 1994;243(5):249-55. doi: 10.1007/BF02191583.
D1-dopamine receptor binding in the brain was determined by positron emission tomography (PET) in five patients with Huntington's disease, in one asymptomatic gene carrier and in five control subjects. [11C] SCH 23390 was used as the radioligand. Brain morphology was recorded by MRI. The patients who all had a mild to moderate functional impairment showed an almost 50% reduction of putamen volume as well as D1-dopamine receptor density as compared to the controls. The total D1-dopamine receptor number in the putamen was reduced by 75% in the patient group. A similar reduction was found for the caudate nucleus. The asymptomatic gene carrier had volume and density values in the lower range of the control subjects. In the frontal neocortex there also tended to be a reduced D1-dopamine receptor binding in the symptomatic patients. The results indicate that [11C] SCH 23390 binding in combination with MRI can be used as a sensitive marker for early brain degeneration in Huntington's disease. This marker may be useful to monitor the pathophysiological effect of the disease gene and also to follow therapeutic interventions aiming at preventing the degenerative process.
采用正电子发射断层扫描(PET)技术,对5例亨廷顿病患者、1例无症状基因携带者及5名对照者大脑中的D1 - 多巴胺受体结合情况进行了测定。使用[11C] SCH 23390作为放射性配体。通过磁共振成像(MRI)记录脑形态。所有患者均有轻度至中度功能障碍,与对照组相比,壳核体积及D1 - 多巴胺受体密度均降低了近50%。患者组壳核中D1 - 多巴胺受体总数减少了75%。尾状核也有类似程度的减少。无症状基因携带者的体积和密度值处于对照组的较低范围。有症状患者的额叶新皮质中D1 - 多巴胺受体结合也有减少趋势。结果表明,[11C] SCH 23390结合MRI可作为亨廷顿病早期脑变性的敏感标志物。该标志物可能有助于监测疾病基因的病理生理效应,也有助于跟踪旨在预防变性过程的治疗干预。